Removal and Absorption of Antibiotics in Patients with Renal Failure Undergoing Peritoneal Dialysis
Authors: PAUL A. GREENBERG
Journal: Annals of Internal Medicine (1967)

Article1 March 1967Removal and Absorption of Antibiotics in Patients with Renal Failure Undergoing Peritoneal DialysisTetracycline, Chloramphenicol, Kanamycin, and ColistimethatePAUL A. GREENBERG, M.D., JAY P. SANFORD, M.D.PAUL A. GREENBERG, M.D.Search for more papers by this author, JAY P. SANFORD, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-66-3-465 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptGram-negative bacterial infections frequently complicate the management of patients undergoing peritoneal dialysis for renal failure. All require immediate and vigorous antibiotic therapy. Because the antibiotics recommended to effectively treat such infections frequently have toxic side effects, the dosage and frequency of administration of these agents become a critical factor in the care of uremic patients.The work of Kunin and associates (1-3) has provided valuable information regarding the dosage schedule of many of the antibiotics commonly used in patients with impaired renal function. In addition, these authors presented some data on the removal of antibiotics by hemodialysis. In recent years...References1. KUNINREESMERRILLFINLAND CMSBJPM: Persistence of antibiotics in blood of patients with acute renal failure. I. Tetracycline and chlortetracycline. J. Clin. Invest. 38: 1487, 1959. CrossrefMedlineGoogle Scholar2. KUNINGLAZKOFINLAND CMAJM: Persistence of antibiotics in blood of patients with acute renal failure. II. Chloramphenicol and its metabolic products in the blood of patients with severe renal disease or hepatic cirrhosis. Ibid., p. 1498. Google Scholar3. KUNINFINLAND CMM: Persistence of antibiotics in blood of patients with acute renal failure. III. Penicillin, streptomycin, erythromycin and kanamycin. Ibid., p. 1509. Google Scholar4. SHEARSHINABERGERBARRY LJHKG: Peritoneal transport of antibiotics in man. New Eng. J. Med. 272: 666, 1965. CrossrefMedlineGoogle Scholar5. ROSEROTHKOCH HDDAML: Serum tetracycline levels during peritoneal dialysis. Amer. J. Med. Sci. 250: 66, 1965. CrossrefMedlineGoogle Scholar6. MACKAYKAYE DND: Serum concentrations of colistin in patients with normal and impaired renal function. New Eng. J. Med. 270: 394, 1964. CrossrefMedlineGoogle Scholar7. REINARZMCINTOSH JADA: Lincomycin excretion in patients with normal renal function, azotemia, and with hemo- and peritoneal dialysis. Antimicrob. Agents Chemother., p. 232, 1966. Google Scholar8. MAXWELLROCKNEYKLEEMANTWISS MHRECRMR: Peritoneal dialysis. I. Technique and applications. JAMA 170: 917, 1959. CrossrefMedlineGoogle Scholar9. IBSENSAUNDERSURIST KHRLMR: Fluorometric determination of oxytetracycline in biological material. Anal. Biochem. 5: 505, 1963. CrossrefMedlineGoogle Scholar10. BOEN ST: Kinetics of peritoneal dialysis: a comparison with the artificial kidney. Medicine (Balt.) 40: 243, 1961. CrossrefGoogle Scholar11. CUTTER LABORATORIES: "Peridial® 1½-D. Peridial® 7-D (manufacturer's insert)." Publication No. 14-7470-004. Rev. Oct. 1964. Google Scholar12. BULGERBENNETTBOEN RJJVST: Intraperitoneal administration of broadspectrum antibiotics in patients with renal failure. JAMA 194: 1198, 1965. CrossrefMedlineGoogle Scholar13. RUEDY J: Effects of peritoneal dialysis on physiological disposition of oxacillin, ampicillin and tetracycline in patients with renal disease. Canad. Med. Ass. J. 94: 257, 1966. MedlineGoogle Scholar14. SHILS ME: Some metabolic aspects of tetracyclines. Clin. Pharmacol. Ther. 3: 321, 1962. CrossrefMedlineGoogle Scholar15. SHILS ME: Renal disease and the metabolic effects of tetracycline. Ann. Intern. Med. 58: 389, 1963. LinkGoogle Scholar16. SOLOMONGALLOWAYPATTERSON MNCR: The kidney and tetracycline toxicity. Missouri Med. 62: 283, 1965. MedlineGoogle Scholar17. FARHATSCHELHARTMUSSELMAN SMDLMM: Clinical toxicity of antibiotics correlated with animal studies. Arch. Surg. (Chicago) 76: 762, 1958. CrossrefGoogle Scholar18. BATEMANBARBERIOGRICEKLOPPPIERPONT JCJRPCTH: Fatal complications of intensive antibiotic therapy in patients with neoplastic disease. Arch. Intern. Med. (Chicago) 90: 763, 1952. CrossrefGoogle Scholar19. SETOLEPPER JTMH: The effect of chlortetracycline, oxytetracycline, and tetracycline administered intravenously on hepatic fat content. A quantitative method of study including failure of some vitamins and other drugs to mitigate the effect. Antibiot. Chemother. (Basel) 4: 666, 1954. Google Scholar20. LEPPERWOLFEZIMMERMANCALDWELLSPIESDOWLING MHCKHJERHWHF: Effect of large doses of aureomycin on human liver. Arch. Intern. Med. (Chicago) 88: 271, 1951. CrossrefGoogle Scholar21. SCHULTZADAMSONWORKMANNORMAN JCJSWWTD: Fatal liver disease after intravenous administration of tetracycline in high dosage. New Eng. J. Med. 269: 999, 1963. CrossrefMedlineGoogle Scholar22. WHALLEYADAMSCOMBES PJRHB: Tetracycline toxicity in pregnancy. Liver and pancreatic dysfunction. JAMA 189: 357, 1964. CrossrefMedlineGoogle Scholar23. WRUBLELADMANBRITTCUMMINS LDAJLGAJ: Hepatotoxicity produced by tetracycline overdosage. JAMA 192: 6, 1965. CrossrefMedlineGoogle Scholar24. SCHIFFER MA: Fatty liver associated with administration of tetracycline in pregnant and non-pregnant women. Amer. J. Obstet. Gynec. 96: 326, 1966. CrossrefMedlineGoogle Scholar25. GROVERANDALL DCWA: Chloramphenicol, in Assay Methods of Antibiotics. A Laboratory Manual. Medical Encyclopedia, Inc., New York, 1955, p. 66. Google Scholar26. GLAZKOWOLFDILLBRATTON AJLMWAAC: Biochemical studies on chloramphenicol (Chloromycetin). II. Tissue distribution and excretion studies. J. Pharmacol. Exp. Ther. 96: 445, 1949. MedlineGoogle Scholar27. GLAZKODILLREBSTOCK AJWAMC: Biochemical studies on chloramphenicol (Chloromycetin). III. Isolation and identification of metabolic products in urine. J. Biol. Chem. 183: 679, 1950. CrossrefGoogle Scholar28. HUGULEY CM: Drug-induced blood dyspasias. DM, October 1963. Google Scholar29. SUHRLANDWEISBERGER LGAS: Chloramphenicol toxicity in liver and renal disease. Arch. Intern. Med. (Chicago) 112: 747, 1963. CrossrefMedlineGoogle Scholar30. MCCURDY PR: Plasma concentrations of chloramphenicol and bone marrow suppression. Blood 21: 363, 1963. CrossrefGoogle Scholar31. GROVERANDALL DCWA: Streptomycin and dihydrostreptomycin, in Assay Methods of Antibiotics. A Laboratory Manual. Medical Encyclopedia, Inc., New York, 1955, pp. 34-36. Google Scholar32. BUNNBALTCHKRAJNYAK PAAO: Clinical experience with kanamycin. Ann. N. Y. Acad. Sci. 76: 109, 1958. CrossrefMedlineGoogle Scholar33. WHITEKNIGHT AV: Kanamycin: pharmacological, microbiological, and clinical observations. Ibid., p. 277. Google Scholar34. COHNCOTLAR IAM: Intraperitoneal kanamycin. Ann. Surg. 155: 532, 1962. CrossrefMedlineGoogle Scholar35. KUNINFINLAND CMM: Restrictions imposed on antibiotic therapy by renal failure. Arch. Intern. Med. (Chicago) 104: 1030, 1959. CrossrefMedlineGoogle Scholar36. FROSTHAWKINSDALY JOJEJF: Kanamycin. II. Ototoxicity. Amer. Rev. Resp. Dis. 82: 23, 1960. MedlineGoogle Scholar37. MURDOCH JM: Discussion, in Kanamycin: appraisal after eight years of clinical application. Ann. N. Y. Acad. Sci. 132: 974, 1966. Google Scholar38. MULLETTKEATS RDAS: Apnea and respiratory insufficiency after intraperitoneal administration of kanamycin. Surgery 49: 530, 1961. MedlineGoogle Scholar39. REAM CR: Respiratory and cardiac arrest after intravenous administration of kanamycin with reversal of toxic effects by neostigmine. Ann. Intern. Med. 59: 384, 1963. LinkGoogle Scholar40. EDWARDSWHYTE KDHM: Streptomycin poisoning in renal failure. An indication for treatment with an artificial kidney. Brit. Med. J. 1: 752, 1959. CrossrefMedlineGoogle Scholar41. DOYLE JE: Discussion, in Kanamycin: an appraisal after eight years of clinical application. Ann. N. Y. Acad. Sci. 132: 983, 1966. Google Scholar42. ORYWILLIAMSCAMPREGESTERMORGEN EMTWFARFRO: Kanamycin in the treatment of patients with diminished kidney function. Ibid., p. 933. Google Scholar43. GROVERANDALL DCWA: Polymyxin, in Assay Methods of Antibiotics. A Laboratory Manual. Medical Encyclopedia, Inc., New York, 1955, pp. 86-88. Google Scholar44. WRIGHTWELCH WWH: Chemical, biological, and clinical observations on colistin, in Antibiotics Annual, 1959-1960. Antibiotica, Inc., New York, 1960, pp. 61-74. Google Scholar45. FEKETYNORMANCLUFF FRPSLE: Treatment of gram-negative bacillary infections with colistin: the toxicity and efficacy of large doses in forty-eight patients. Ann. Intern. Med. 57: 214, 1962. LinkGoogle Scholar46. WOLINSKYHINES EJD: Neurotoxic and nephrotoxic effects of colistin in patients with renal disease. New Eng. J. Med. 266: 759, 1962. CrossrefMedlineGoogle Scholar47. ROBERTSKIRBY CEWM: Colistin in the treatment of hospitalized patients with pseudomonas infections, in Antimicrobial Agents Annual, 1960. Plenum Press, Inc., New York, 1961, pp. 409-423. Google Scholar48. RICHETARDAILLOUSULTAN GRY: Accidents neuro-psychiques chez des uremiques chroniques traites par le methane-sulfonate de colistine. Bull. Soc. Med. Hop. Paris 113: 1199, 1962. MedlineGoogle Scholar49. YOWTANSHANESCHONFELDABU-NASSAR EMELSH: Colistin (coly-mycin) in resistant bacterial infections. A clinical appraisal. Arch. Intern. Med. (Chicago) 108: 664, 1961. CrossrefMedlineGoogle Scholar50. NORDHOEPRICH NMPD: Polymyxin B and colistin. A critical comparison. New Eng. J. Med. 270: 1030, 1964. CrossrefMedlineGoogle Scholar51. PERKINS RL: Apnea with intramuscular colistin therapy. JAMA 190: 421, 1964. CrossrefMedlineGoogle Scholar52. PARISIKAPLAN AFMH: Apnea during treatment with sodium colistimethate. JAMA 194: 298, 1965. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Dallas, TexasFrom the Department of Internal Medicine, the University of Texas Southwestern Medical School, and Parkland Memorial Hospital, Dallas, Tex.These studies were supported in part by the Warner-Lambert Research Institute, Research Affiliate of Warner-Chilcott Laboratories, Morris Plains, N. J.Dr. Greenberg was the recipient of a postdoctoral traineeship under training grant T1-A1-30, the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.Requests for reprints should be addressed to Jay P. Sanford, M.D., Department of Internal Medicine, the University of Texas Southwestern Medical School, 5323 Harry Hines Blvd., Dallas, Tex. 75235. Nextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byTetracyclines, Glycylcyclines, and ChloramphenicolEffective removal of colistin methanesulphonate and formed colistin during intermittent haemodialysis in a patient infected by polymyxin-only-susceptible Pseudomonas aeruginosaPharmacokinetics of Colistin Methanesulfonate and Formed Colistin in End-Stage Renal Disease Patients Receiving Continuous Ambulatory Peritoneal DialysisSuccessful Treatment of Extensively Drug-Resistant Acinetobacter baumannii Peritoneal Dialysis Peritonitis with Intraperitoneal Polymyxin B and Ampicillin-SulbactamLuces y sombras en el uso de colistina: falta mucho por conocerPharmacokinetic evaluation of colistin sodiumTetracyclineColistin and Polymyxin B in Critical CarePolymyxin antibiotics for gram-negative infectionsPolymyxin B Sulfate and Colistin: Old Antibiotics for Emerging Multiresistant Gram-Negative BacteriaPharmacologic alterations of peritoneal transport rates and pharmacokinetics of the peritoneumKComments on Dialysis Solution, Antibiotic Transport, Poisonings, and Novel Uses of Peritoneal DialysisPharmacological Considerations for Renal Failure and DialysisStudies of quinacrine and of tetracycline for non-surgical female sterilizationComments on dialysis solution, antibiotic transport, poisoning, and novel uses of peritoneal dialysisEffect of intrauterine administration of tetracyclines on cynomolgus monkeysManagement of chloramphenicol intoxication in infancy by charcoal hemoperfusionDrugs and Peritoneal DialysisDrugs and DialysisPractical Use of Peritoneal DialysisPharmacological Aspects of Renal Failure and DialysisFatal Aplastic Anemia Following Topical Administration of Ophthalmic ChloramphenicolAntibiotic Pharmacokinetics and Clinical Application in Renal InsufficiencyManagement of neonatal gentamicin overdosageDrug Therapy in Renal Failure: Dosing Guidelines for Adults Part I: Antimicrobial Agents, AnalgesicsWILLIAM M. BENNETT, M.D., RICHARD S. MUTHER, M.D., RICHARD A. PARKER, M.D., PETER FEIG, M.D., GAIL MORRISON, M.D., THOMAS A. GOLPER, M.D., IRWIN SINGER, M.D.Treatment of an infant with severe chloramphenicol intoxication using charcoal-column hemoperfusionPeritoneal DialysisPharmacologic Aspects of Regular Dialysis TreatmentPharmacokinetic Aspects of the Dialysis of DrugsAntibiotic Concentrations in Ascitic Fluid of Patients with Ascites and Bacterial PeritonitisDALE N. GERDING, M.D., WENDELL H. HALL, M.D., Ph.D., F.A.C.P., ELIZABETH A. SCHIERL, B.S.Guidelines for Drug Therapy in Renal FailureWILLIAM M. BENNETT, M.D., F.A.C.P., IRWIN SINGER, M.D., F.A.C.P., THOMAS GOLPER, M.D., PETER FEIG, M.D., CECIL J. COGGINS, M.D.Drug administration in renal failureComparative Penetration of Amikacin, Gentamicin, and Penicillin G into Exudate Fluid in Experimental Sterile PeritonitisAntibiotic Penetrance of Ascitic Fluid in DogsAntibiotic Management in Renal FailureEffect of Peritoneal Dialysis on Serum Levels of Tobramycin and ClindamycinA controlled trial of intraperitoneal cephaloridineadministration in peritonitisDrug Selection and Dosage in Renal InsufficiencyAntibiotics and the KidneyPeritoneal transfer of kanamycin and its use in peritoneal dialysisPeritoneal Dialysis-1973Peritoneal Dialysis: A ReviewDialysis of Poisons and DrugsDepression of cardiac function by streptomycin and other antimicrobial agentsThe TetracyclinesColistin and Sodium ColistimethateColistimethate OverdosageDrug Information Analysis Service-the Dias RoundsHÆMOLYTIC-URÆMIC SYNDROME AND HEPARIN THERAPYESTIMATING DRUG-DOSAGE REGIMENSMETHOD FOR ESTIMATING INDIVIDUAL DRUG-DOSAGE REGIMENSPeritoneal dialysis in colistin intoxication: Report of a caseHost Determinants of Response to Antimicrobial AgentsThe Effects of Renal Impairment, Peritoneal Dialysis, and Hemodialysis on Serum Sodium Colistimethate LevelsNORMA J. GOODWIN, M.D., ELI A. FRIEDMAN, M.D.Medical management of chronic renal failureAbsorption of antibiotics during peritoneal dialysis in patients with renal failureGeneral Considerations Concerning the Penicillins, Streptomycin and Allied Drugs, and the TetracyclinesGeneral Considerations Concerning Chloramphenicol, Erythromycin and Allied Drugs, the Polymyxins, Bacitracin, Vancomycin, Ristocetin, Cycloserine, the Cephalosporins, the Chemotherapeutic Drugs, and the Antimycotic DrugsA Guide to Use of Antibiotics in Patients with Renal Disease A Table of Recommended Doses and Factors Governing Serum LevelsCALVIN M. KUNIN, M.D., F.A.C.P. 1 March 1967Volume 66, Issue 3Page: 465-479KeywordsAntibioticsChloramphenicolGram negative bacterial infectionsHospital medicineInfectious diseasesMedical dialysisPatientsPeritoneal dialysisRenal critical careRenal failure Issue Published: 1 March 1967 Copyright & PermissionsCopyright ©, 1967, by The American College of PhysiciansPDF downloadLoading ...